Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Halozyme Therapeutics, Inc., Celldex Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Halozyme Therapeutics, Inc., Celldex Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Halozyme Therapeutics, Inc., Celldex Therapeutics and Inc.

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.

Latest Biotechnology and Halozyme Therapeutics, Inc., Celldex Therapeutics, Inc. Stock News

As of February 25, 2026, Halozyme Therapeutics, Inc. had a $8.3 billion market capitalization, compared to the Biotechnology median of $283.1 million. Halozyme Therapeutics, Inc.’s stock is up 2.4% in 2026, down 4.4% in the previous five trading days and up 20.26% in the past year.

Currently, Halozyme Therapeutics, Inc.’s price-earnings ratio is 27.5. Halozyme Therapeutics, Inc.’s trailing 12-month revenue is $1.4 billion with a 22.7% net profit margin. Year-over-year quarterly sales growth most recently was 51.6%. Analysts expect adjusted earnings to reach $8.016 per share for the current fiscal year. Halozyme Therapeutics, Inc. does not currently pay a dividend.

As of February 25, 2026, Celldex Therapeutics, Inc. had a $2.0 billion market cap, putting it in the 55th percentile of all stocks. Celldex Therapeutics, Inc.’s stock is up 11.5% in 2026, up 28.7% in the previous five trading days and up 44.49% in the past year.

Currently, Celldex Therapeutics, Inc. does not have a price-earnings ratio. Celldex Therapeutics, Inc.’s trailing 12-month revenue is $2.6 million with a % net profit margin. As of February 25, 2026, Celldex Therapeutics, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-3.589 per share for the current fiscal year. Celldex Therapeutics, Inc. does not currently pay a dividend.

How We Compare Halozyme Therapeutics, Inc., Celldex Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Halozyme Therapeutics, Inc., Celldex Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Halozyme Therapeutics, Inc., Celldex Therapeutics and Inc. Stock Value Grades

Company	Ticker	Value
Halozyme Therapeutics, Inc.	HALO	D
Celldex Therapeutics, Inc.	CLDX	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Halozyme Therapeutics, Inc. has a Value Score of 40, which is Expensive. Celldex Therapeutics, Inc. has a Value Score of 14, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Halozyme Therapeutics, Inc., Celldex Therapeutics or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Halozyme Therapeutics, Inc., Celldex Therapeutics or Inc. is the better investment when it comes to value.

Halozyme Therapeutics, Inc., Celldex Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
Halozyme Therapeutics, Inc.	HALO	B
Celldex Therapeutics, Inc.	CLDX	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Halozyme Therapeutics, Inc. has a Growth Score of 68, which is Strong. Celldex Therapeutics, Inc. has a Growth Score of 29, which is Weak.

The Growth Grade Winner: Halozyme Therapeutics, Inc.

As you can clearly see from the Growth Grade breakdown above, Halozyme Therapeutics, Inc. has a more attractive growth grade than Celldex Therapeutics, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Halozyme Therapeutics, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Halozyme Therapeutics, Inc., Celldex Therapeutics and Inc.’s Momentum Grades

Company	Ticker	Momentum
Halozyme Therapeutics, Inc.	HALO	C
Celldex Therapeutics, Inc.	CLDX	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Halozyme Therapeutics, Inc. has a Momentum Score of 47, which is Average. Celldex Therapeutics, Inc. has a Momentum Score of 71, which is Strong.

The Momentum Grade Winner: Celldex Therapeutics, Inc.

As you can clearly see from the Momentum Grade breakdown above, Celldex Therapeutics, Inc. is considered to have stronger momentum compared to Halozyme Therapeutics, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Celldex Therapeutics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Halozyme Therapeutics, Inc., Celldex Therapeutics and Inc. Grades

In addition to Growth, Momentum and Value, A+ Investor also provides grades for Estimate Revisions and Quality.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Halozyme Therapeutics, Inc., Celldex Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Halozyme Therapeutics, Inc., Celldex Therapeutics or Inc. Stock?

Overall, Halozyme Therapeutics, Inc. stock has a Value Score of 40, Growth Score of 68 and Momentum Score of 47.

Celldex Therapeutics, Inc. stock has a Value Score of 14, Growth Score of 29 and Momentum Score of 71.

Comparing Halozyme Therapeutics, Inc., Celldex Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.